N-aryl oxamic acids
The present disclosure relates to novel N-aryl oxamic acid based inhibitors for Mycobacterium tuberculosis protein tyrosine phosphatase B (mPTPB), and to the method of making and using the novel N-aryl oxamic acid based inhibitors. More specifically, compounds provided in this disclosure can be used to inhibit Mycobacterium tuberculosis protein tyrosine phosphatase B (mPTPB) and to treat a patient having a Tuberculosis disease.
1. A compound of formula I:
or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt thereof, wherein:
(R 1 ) n represents 1-3 independent R 1 being attached to the phenyl ring wherein n is 1-3, wherein each of said 1-3 R 1 independently represents a H, F, Cl, Br, I, —CN, —OR 2 , —COOR 3 , —NR 4 R 5 , —CO—R 6 , —SO 2 NR 7 R 8 , an optionally substituted C 1 -C 5 branched or unbranched alkyl chain, an optionally substituted C 3 -C 8 cyclic alkyl, an optionally substituted aryl, or an optionally substituted heteroaryl comprising one or more O, N, or S, or when n is 2, two independent R 1 can join together to form a fused bicyclic ring with the phenyl ring; and
R 2 -R 8 each independently represents a H, an optionally substituted C 1 -C 8 branched or unbranched alkyl chain, an optionally substituted C 3 -C 8 cyclic alkyl, an optionally substituted aryl, or an optionally substituted heteroaryl comprising one or more O, N, or S, or a nitrogen protecting group.
2. The compound of claim 1 , wherein —HN—C(O)—COOH is on the para position of the directly attached phenyl group.
3. The compound of claim 1 , wherein one or more hydrogen on R 1 -R 8 can be optionally substituted by one or more —OH, —F, —Cl, —Br, —CN, or C 1 -C 4 alkoxy, or an optionally substituted phenyl group.
4. The compound of claim 1 , wherein each of said 1-3 R 1 independently represents a H, F, Cl, Br, I, —CN, —CF 3 , —OH, —OCF 3 , —COCF 3 , —COOCH 3 , —COOH, —N(CH 3 ) 2 , —NHBoc, —SO 2 NH 2 , —OCH 2 Ph, or two R 1 groups jointly form a ring to make a naphthalene ring with the phenyl group that the R 1 is directly attached.
5. The compound of claim 1 , wherein the compound is selected from the group consisting of:
6. A method for treating a patient having a Tuberculosis disease with a compound of claim 1 , or a stereoisomer, tautomer, solvate, pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the compound of claim 1 inhibits Mycobacterium tuberculosis protein tyrosine phosphatase B (mPTPB).
8. The method of claim 6 , wherein the compound is selected from one or more compound of claim 5 .